NCT04097444View on ClinicalTrials.gov

CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

PHASE2UnknownINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 11, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Metastatic Colorectal Cancer
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

5-fluorouracil

Given IV

DRUG

Leucovorin calcium

Given IV

DRUG

Irinotecan hydrochloride

Given IV

DRUG

Oxaliplatin

Given IV

DRUG

Capecitabine

Given PO

Trial Locations (1)

104-0053

RECRUITING

Ac Medical Inc., Chuo Ku

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY